Q1 EPS Estimate for Gain Therapeutics Raised by Analyst

Gain Therapeutics, Inc. (NASDAQ:GANX) – Analysts at Roth Capital boosted their Q1 2025 EPS estimates for shares of Gain Therapeutics in a research report issued to clients and investors on Sunday, March 30th. Roth Capital analyst B. Pachaiyappan now forecasts that the company will post earnings of ($0.14) per share for the quarter, up from their previous forecast of ($0.17). Roth Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.00) per share. Roth Capital also issued estimates for Gain Therapeutics’ Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($0.73) EPS and FY2026 earnings at ($1.13) EPS.

Gain Therapeutics (NASDAQ:GANX) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.07.

A number of other analysts have also recently commented on the company. Scotiabank initiated coverage on Gain Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $12.00 price objective for the company. Roth Mkm reissued a “buy” rating and issued a $7.00 price objective on shares of Gain Therapeutics in a research report on Tuesday, December 24th. Chardan Capital restated a “buy” rating and set a $6.00 target price on shares of Gain Therapeutics in a research report on Friday, March 28th. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Gain Therapeutics in a report on Monday, March 17th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $8.20.

Gain Therapeutics Stock Performance

Gain Therapeutics stock opened at $1.81 on Wednesday. Gain Therapeutics has a fifty-two week low of $0.89 and a fifty-two week high of $4.04. The company has a market capitalization of $48.01 million, a price-to-earnings ratio of -1.65 and a beta of 0.14. The stock has a fifty day moving average of $2.20 and a two-hundred day moving average of $2.07. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.99 and a current ratio of 2.99.

Institutional Investors Weigh In On Gain Therapeutics

Several hedge funds have recently modified their holdings of GANX. Jones Financial Companies Lllp raised its stake in Gain Therapeutics by 83.6% during the fourth quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company’s stock worth $212,000 after purchasing an additional 44,750 shares during the period. Geode Capital Management LLC increased its holdings in shares of Gain Therapeutics by 48.0% during the 3rd quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock worth $484,000 after buying an additional 88,236 shares during the last quarter. Benedict Financial Advisors Inc. purchased a new position in shares of Gain Therapeutics in the 4th quarter worth $35,000. Sprott Inc. acquired a new position in Gain Therapeutics in the fourth quarter valued at $30,000. Finally, Northern Trust Corp grew its position in Gain Therapeutics by 88.2% during the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock valued at $183,000 after acquiring an additional 39,642 shares during the period. 11.97% of the stock is owned by institutional investors and hedge funds.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.